Initial proof-of-concept demonstrated that global DNA demethylation using 5-aza-2′-deoxycytidine can reactivate FMR1 in FXS lymphoblastoid cells; however, this approach faces significant translational challenges due to its lack of specificity for particular loci [52]. The gene discussed is FMR1; the disease is fragile X syndrome.